Inactive Placebo

Preclinical

JJohns Hopkins University

Inactive Placebo is one of 4 therapeutic programs targeting Mood. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

MoodRecruiting

MoodPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Mood

#DrugCompanyPhaseTrials

Nuplazid

AACADIA Pharmaceuticals Inc.

Preclinical

1 2

Psilocybin

COMPASS Pathways

Preclinical

1 3

Sulpiride

PPhilipps University Marburg

Preclinical

1 4

Inactive Placebo

JJohns Hopkins University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Depressive Disorder, Major

NCT06308653

Q4 2027

Phase 1Not yet recruiting

Study completion

NCT07818564

Q4 2028

PreclinicalRecruiting

Mood

NCT07610135

Clinical

Trials by Indication[1]

Mood1 trial

PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment

Recruiting·JJohns Hopkins University·Preclinical·NCT07610135·20 enrolled

Depressive Disorder, Major1 trial

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)

Active, not recruiting·UUsona Institute·Phase 3·NCT06308653·238 enrolled

Unspecified1 trial

Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation

Not yet recruiting·BBrown University·Phase 1·NCT07818564·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Inactive Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Inactive Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: JJohns Hopkins University

Inactive Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Mood1 trial

Depressive Disorder, Major1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News